Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from BriaCell Therapeutics ( (TSE:BCT) ).
BriaCell Therapeutics has announced promising results from its Phase 2 clinical study of Bria-IMT in patients with metastatic breast cancer, with 52% of the most recent 25-patient cohort surpassing the one-year survival milestone. This achievement exceeds the current standard of care for similar patients, particularly those who have undergone extensive prior treatments. The study highlights the potential of Bria-IMT in combination with checkpoint inhibitors, and its ongoing investigation in a Phase 3 trial could further enhance its impact on cancer treatment.
The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$15.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
BriaCell Therapeutics has a challenging financial position with no revenue and consistent losses, heavily impacting its stock score. Despite this, recent corporate developments in cancer treatment provide some potential upside. Technical indicators are mixed, and valuation concerns persist with a negative P/E ratio. The company’s reliance on external financing is a notable risk.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care.
Average Trading Volume: 17,339
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$26.77M
Learn more about BCT stock on TipRanks’ Stock Analysis page.